Longeveron (LGVN) Competitors $1.32 -0.04 (-2.94%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LGVN vs. GNTA, SRZN, ABOS, SKYE, MCRB, STRO, MNOV, ANRO, IKNA, and PYRGFShould you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Genenta Science (GNTA), Surrozen (SRZN), Acumen Pharmaceuticals (ABOS), Skye Bioscience (SKYE), Seres Therapeutics (MCRB), Sutro Biopharma (STRO), MediciNova (MNOV), Alto Neuroscience (ANRO), Ikena Oncology (IKNA), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical products" industry. Longeveron vs. Its Competitors Genenta Science Surrozen Acumen Pharmaceuticals Skye Bioscience Seres Therapeutics Sutro Biopharma MediciNova Alto Neuroscience Ikena Oncology PyroGenesis Canada Genenta Science (NASDAQ:GNTA) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability. Does the MarketBeat Community favor GNTA or LGVN? Longeveron received 11 more outperform votes than Genenta Science when rated by MarketBeat users. Likewise, 90.00% of users gave Longeveron an outperform vote while only 87.50% of users gave Genenta Science an outperform vote. CompanyUnderperformOutperformGenenta ScienceOutperform Votes787.50% Underperform Votes112.50%LongeveronOutperform Votes1890.00% Underperform Votes210.00% Do analysts prefer GNTA or LGVN? Genenta Science presently has a consensus target price of $25.00, indicating a potential upside of 544.33%. Longeveron has a consensus target price of $8.67, indicating a potential upside of 556.57%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk and volatility, GNTA or LGVN? Genenta Science has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Is GNTA or LGVN more profitable? Genenta Science has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. Genenta Science's return on equity of 0.00% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A Longeveron -967.49%-142.43%-100.84% Do institutionals & insiders hold more shares of GNTA or LGVN? 15.1% of Genenta Science shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 11.2% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer GNTA or LGVN? In the previous week, Genenta Science and Genenta Science both had 3 articles in the media. Genenta Science's average media sentiment score of 0.78 beat Longeveron's score of 0.63 indicating that Genenta Science is being referred to more favorably in the media. Company Overall Sentiment Genenta Science Positive Longeveron Positive Which has stronger valuation and earnings, GNTA or LGVN? Genenta Science has higher earnings, but lower revenue than Longeveron. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$12.60MN/AN/ALongeveron$2.23M8.86-$21.41M-$6.28-0.21 SummaryGenenta Science beats Longeveron on 8 of the 15 factors compared between the two stocks. Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGVN vs. The Competition Export to ExcelMetricLongeveronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.71M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.218.6727.1419.96Price / Sales8.86262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book0.496.597.064.69Net Income-$21.41M$143.75M$3.23B$248.14M7 Day Performance11.86%3.72%2.67%2.39%1 Month Performance-10.20%11.01%8.82%6.05%1 Year Performance-27.07%3.87%31.44%13.60% Longeveron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGVNLongeveron3.5316 of 5 stars$1.32-2.9%$8.67+556.6%+65.9%$19.71M$2.23M-0.2120News CoverageGap DownGNTAGenenta Science2.7712 of 5 stars$4.00flat$25.00+525.0%+15.8%$73.16MN/A0.007Short Interest ↓SRZNSurrozen3.797 of 5 stars$8.80+3.5%$38.50+337.5%-20.9%$72.78M$11.64M-0.3580Positive NewsABOSAcumen Pharmaceuticals2.1878 of 5 stars$1.27+5.8%$7.33+477.4%-57.0%$72.69MN/A-0.9220Positive NewsShort Interest ↑Analyst RevisionSKYESkye Bioscience1.8156 of 5 stars$2.34-3.7%$16.60+609.4%-78.8%$72.48MN/A-2.8511Analyst RevisionMCRBSeres Therapeutics3.562 of 5 stars$8.15-1.0%$73.67+803.9%-49.5%$71.17M$126.33M-35.43330Positive NewsSTROSutro Biopharma4.61 of 5 stars$0.83-2.5%$6.11+639.6%-78.4%$69.82M$66.43M-0.51240Positive NewsMNOVMediciNova2.1401 of 5 stars$1.42+0.7%$9.00+533.8%+2.3%$69.65M$1M-6.1710Positive NewsANROAlto Neuroscience1.6891 of 5 stars$2.55-0.8%$15.40+503.9%-79.4%$69.03MN/A-1.09N/AIKNAIkena Oncology3.6173 of 5 stars$1.47+3.5%$3.00+104.1%-22.7%$68.53M$659K-1.2070Positive NewsShort Interest ↓PYRGFPyroGenesis Canada0.1612 of 5 stars$0.37-0.6%N/A-20.8%$68.51M$9.14M-6.1290Short Interest ↑Gap Down Related Companies and Tools Related Companies GNTA Alternatives SRZN Alternatives ABOS Alternatives SKYE Alternatives MCRB Alternatives STRO Alternatives MNOV Alternatives ANRO Alternatives IKNA Alternatives PYRGF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGVN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
